Visual Abstract

Background: Both CNS reduced dopaminergic and elevated sympathetic tone converge to stimulate a POS/PI phenotype that promotes cardiovascular disease (CVD) and augments postprandial hyperglycemia in T2DM. BQR, a sympatholytic dopamine agonist for treatment of T2DM, improves postprandial dysglycemia and reduces CVD events.

Aim: To examine the effect of BQR on POS/PI/ER stress phenotype of peripheral blood mononuclear (PBMN) cells in T2DM.

Study Design: 15 T2DM subjects treated with a GLP-1 RA received BQR (3.2 mg/day) for 16 weeks. Endothelial function was measured by post-occlusion hyperemia. Postprandial glucose metabolism was assessed by meal tolerance test with the double tracer technique (Endo Diab Metab 2018:e00034). Blood PBMN cells were isolated and expression of genes (RT-qPCR) from the following cell physiologic systems was quantitated: (i) multiple-pathway antioxidant regulators that increase in response to systemic oxidative stress (OS); (ii) genes known to be expressed and operative in the ER stress response (including associated autophagy) (see Table for specific gene details).

Results: See Table.

Conclusion: BQR reduces postprandial dysglycemia, improves endothelial function, and markedly attenuates the POS/PI/ER stress condition in plasma and PBMN cells of T2DM subjects, providing potential mechanisms for BQR’s CV protective effect.


M. Ezrokhi: Employee; Self; VeroScience LLC. A. H. Cincotta: Employee; Self; VeroScience LLC, Employee; Spouse/Partner; VeroScience LLC, Stock/Shareholder; Self; VeroScience LLC. E. Cersosimo: None. J. M. Adams: None. M. Alatrach: None. C. Agyin: None. C. L. Triplitt: Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk, Xeris Pharmaceuticals, Inc. N. Cominos: Employee; Self; VeroScience LLC. R. A. Defronzo: Other Relationship; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk, Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Speaker’s Bureau; Self; AstraZeneca, Novo Nordisk.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at